Immunomedics Inc. (NASDAQ:IMMU) and Cellectis S.A. (NASDAQ:CLLS), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunomedics Inc.	N/A	0.00	315.34M	-1.38	0.00
Cellectis S.A.	21.43M	35.88	78.69M	-2.11	0.00

Table 1 highlights Immunomedics Inc. and Cellectis S.A.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Immunomedics Inc. and Cellectis S.A.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunomedics Inc.	0.00%	-114.5%	-56.8%
Cellectis S.A.	-367.20%	-23%	-18.8%

Risk & Volatility

Immunomedics Inc. is 109.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 2.09. Cellectis S.A.’s 74.00% more volatile than Standard and Poor’s 500 which is a result of the 1.74 beta.

Liquidity

Immunomedics Inc.’s Current Ratio is 15.9 while its Quick Ratio is 15.9. On the competitive side is, Cellectis S.A. which has a 11.2 Current Ratio and a 11.2 Quick Ratio. Immunomedics Inc. is better positioned to pay off short and long-term obligations compared to Cellectis S.A.

Analyst Ratings

Immunomedics Inc. and Cellectis S.A. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Immunomedics Inc.	0	1	7	2.88
Cellectis S.A.	0	2	1	2.33

Immunomedics Inc. has a 28.69% upside potential and an average target price of $24. Competitively Cellectis S.A. has an average target price of $35.25, with potential upside of 96.16%. The data from earlier shows that analysts view suggest that Cellectis S.A. seems more appealing than Immunomedics Inc.

Insider and Institutional Ownership

Institutional investors owned 87.8% of Immunomedics Inc. shares and 29.4% of Cellectis S.A. shares. About 7.47% of Immunomedics Inc.’s share are owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Immunomedics Inc.	11.4%	14.33%	-9.38%	-34.36%	4.25%	18.5%
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%

For the past year Immunomedics Inc. was more bullish than Cellectis S.A.

Summary

On 6 of the 11 factors Cellectis S.A. beats Immunomedics Inc.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.